Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062073 | 0.92 | MCHR1 (0.51) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL868393 | 0.90 | MCHR1 (0.52) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL868692 | 0.90 | MCHR1 (0.49) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL10027446 | 0.86 | MCHR1 (0.51) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL868477 | 0.85 | MCHR1 (0.53) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL868767 | 0.84 | MCHR1 (0.54) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL870171 | 0.83 | MCHR1 (0.52) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL867652 | 0.82 | MCHR1 (0.45) | MCHR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL870323 | 0.82 | MCHR1 (0.59) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL10027445 | 0.82 | MCHR1 (0.53) | MCHR1DPP4KCNH2DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2437600-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120077795-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXSMITHKLINE LLC (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010141540-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077795-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MCHR1 1/4885DPP4 502/4885KCNH2 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.